ALFA Filings
Every announcement, straight from the exchange
Every Mankind Pharma earnings call announcement on NSE and BSE, newest first, each with its own page.
Time
6 announcements with these filters
Mankind Pharma delivered robust Q2 growth driven by chronic therapies and B-Spec specialty expansion. Strong operating leverage and margin expansion offset muted consumer health performance.
Q2 FY27 revenue ₹4,338 Cr (+17.3% YoY), EBITDA ₹1,175 Cr (27.1% margin), PAT ₹716 Cr (+37.7%). Domestic ex-CH +15.9%, exports +32.7%, CH +1.2%.
Mankind Pharma's FY25 ESG report highlights a 73% carbon reduction since FY21 and 63% renewable energy mix. The company is focused on embedding sustainable practices across manufacturing and its value chain.
Mankind Pharma reported strong Q1 FY27 results with 12.9% revenue growth and 29.1% PAT growth. Strategy focuses on chronic segment expansion, BSV integration, and OTC growth.
Mankind Pharma reported strong Q4 FY26 results with 11.8% revenue growth and 27.1% EBITDA margins, driven by chronic therapy outperformance and steady recovery in acute segments.
Mankind Pharma reported ₹14,278 Cr FY26 revenue, focusing on increasing chronic share (39.9% in Q4) and super-specialty expansion via BSV acquisition.